University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

2-Acetylaminofluorene (CAS 53-96-3)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
liv mgl ski liv mgl ski liv ubl liv ubl 1.22m 7.59m,v

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
(mg/kg/day)
Male Female
liv no positive 17.4

Monkeys: Cancer Test Summary
Monkey Target Sites TD50
(mg/kg/day)
Rhesus Cynomulgus Rhesus Cynomulgus
no positive no test no positive no test

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   liv = liver. mgl = mammary gland. ski = skin. ubl = urinary bladder. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

2-Acetylaminofluorene: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

2-ACETYLAMINOFLUORENE (N-2-fluorenylacetamide, 2-AAF) 53-96-3 62 H m nss eat 32w56 308m 0 15.9mg Miller;canr,24,2018-2026;1964 liv bdc 17.4mg P<.04 + 5.24mg n.s.s. 0/17 3/18 63 H m nss ipj 34w69 308n 0 3.21mg smi adc 7.26mg P<.3 1.18mg n.s.s. 0/8 1/8 per sar no dre P=1. 2.33mg n.s.s. 0/8 0/8 for pam no dre P=1. 1.34mg n.s.s. 1/8 1/8 64 H f syg eat 26w68 347n 0 16.0mg Della Porta;jnci,22,463-471;1959 liv cac e 17.3mg P<.03 4.02mg n.s.s. 1/59 2/8 65 H m syg eat 40w84 347m 0 17.5mg liv cac e 15.3mg P<.003 3.65mg 211.mg 0/39 2/5 66 H m syg eat 26w80 347n 0 12.0mg liv cac e 31.5mg P<.2 5.10mg n.s.s. 0/16 1/7 67 M f asw eat 84w84 213b 0 39.0mg Prier;txap,5,526-542;1963 tba mix e no dre P=1. 8.63mg n.s.s. 14/16 15/18 tba mal e 51.1mg P<.3 + 13.2mg n.s.s. 6/16 10/18 68 M m asw eat 84w84 213b 0 36.0mg tba mal e 17.4mg P<.006 + 7.28mg 200.mg 1/10 9/14 tba mix e 21.7mg P<.2 6.89mg n.s.s. 4/10 10/14 69 M f ays eat 30m30 2034n : 0 6.50mg 13.0mg 26.0mg Wolff;jtxe,33,327-348;1991/pers.comm. liv mix er 2.27mg Z P<.0005 + .869mg 4.73mg 4/24 11/23 17/24 23/23 liv hpc er 3.31mg Z P<.0005 + 1.02mg 8.56mg 3/24 7/23 10/24 19/23 ubl mix er 43.0mg Z P<.0005 + 15.5mg 118.mg 0/24 0/23 0/24 9/23 ubl tcc er 54.1mg Z P<.0005 + 16.7mg 193.mg 0/24 0/23 0/24 7/23 70 M m ays eat 30m30 2034m : 0 6.00mg 12.0mg 24.0mg ubl mix er 2.45mg Z P<.0005 + 1.43mg 4.15mg 0/24 15/24 22/24 24/24 ubl tcc er 4.32mg Z P<.0005 + 2.47mg 7.13mg 0/24 9/24 18/24 21/24 liv mix er 4.61mg Z P<.0005 + 2.16mg 17.1mg 6/24 14/24 10/24 5/24 71 M f b6c eat 82w82 2020m 0 19.5mg 26.0mg 32.5mg Fullerton;faat,16,51-60;1991/Nonoyama 1988/ pers.comm. liv mix er 4.00mg * P<.0005 + 2.97mg 5.45mg 43/117 67/70 89/92 91/95 liv mal er 5.38mg * P<.0005 4.31mg 6.80mg 14/117 60/70 81/92 87/95 ubl mix er 38.3mg Z P<.0005 + 28.0mg 54.3mg 0/108 6/67 18/85 38/93 ubl mal er 64.9mg Z P<.0005 44.0mg 101.mg 0/108 3/67 10/85 26/93 liv hpb er 526.mg * P<.06 215.mg n.s.s. 0/96 2/96 1/96 3/96 72 M f b6c eat 82w82 2020n 0 19.5mg 26.0mg 32.5mg liv mix er 8.80mg * P<.0005 + 7.12mg 11.1mg 9/118 46/71 69/96 78/95 liv mal er 15.9mg * P<.0005 12.6mg 20.5mg 3/118 21/71 48/96 65/95 ubl mix er 71.8mg Z P<.0005 + 48.3mg 113.mg 0/117 0/69 5/95 32/93 ubl mal er 201.mg Z P<.0005 108.mg 464.mg 0/117 0/69 1/95 13/93 73 M f b6c eat 30m30 2034r : 0 6.50mg 13.0mg 26.0mg Wolff;jtxe,33,327-348;1991/pers.comm. liv mix er 3.99mg * P<.0005 + 2.89mg 5.76mg 4/48 31/47 45/47 44/48 liv hpc er 9.49mg Z P<.0005 + 6.56mg 14.2mg 1/48 12/47 28/47 33/48 ubl mix er 47.7mg Z P<.0005 + 26.0mg 86.6mg 0/48 0/47 0/47 20/48 ubl tcc er 89.2mg Z P<.0005 + 45.5mg 198.mg 0/48 0/47 0/47 13/48 74 M m b6c eat 82w82 2020m 0 4.80mg 7.20mg 9.60mg Fullerton;faat,16,51-60;1991/Nonoyama 1988/ pers.comm. liv mix er 2.35mg * P<.0005 + 1.85mg 3.11mg 21/95 53/94 79/94 83/94 liv mal er 5.46mg * P<.0005 4.11mg 7.92mg 12/95 28/94 49/94 59/94 ubl mix er 7.90mg Z P<.0005 + 6.02mg 10.6mg 0/93 0/91 31/92 53/89 ubl mal er 21.2mg Z P<.0005 14.2mg 33.6mg 0/93 0/91 10/92 26/89 liv hpb er 57.3mg * P<.004 31.4mg 276.mg 0/96 4/96 5/96 6/96 75 M m b6c eat 82w82 2020n 0 4.80mg 7.20mg 9.60mg ubl mix er 7.29mg Z P<.0005 + 5.23mg 10.6mg 0/94 1/96 54/96 (17/94) liv mal er 40.8mg * P<.01 21.0mg 2.69gm 4/96 7/96 8/96 15/94 ubl mal er 107.mg * P<.005 48.7mg 772.mg 0/94 0/96 2/96 6/94 liv mix er 32.9mg * P<.04 + 15.2mg n.s.s. 13/96 14/96 15/96 26/94 76 M m b6c eat 30m30 2034o : 0 6.00mg 12.0mg 24.0mg Wolff;jtxe,33,327-348;1991/pers.comm. liv mix er 4.34mg Z P<.0005 + 2.78mg 7.41mg 13/47 29/48 24/48 17/48 ubl mix er 5.02mg Z P<.0005 + 3.48mg 7.16mg 0/47 11/48 45/48 46/48 ubl tcc er 7.52mg Z P<.0005 + 5.00mg 11.0mg 0/47 6/48 33/48 40/48 liv hpc er 14.4mg Z P<.0005 + 7.90mg 31.8mg 6/47 9/48 14/48 9/48 77 M f bal eat 52w52 1665 0 1.04mg 3.12mg 5.85mg 7.67mg 11.2mg Haley;pseb,152,156-159;1976 liv tum ek no dre P=1. .969mg n.s.s. 0/24 0/48 0/48 0/24 0/16 0/8 ubl car ek no dre P=1. - .969mg n.s.s. 0/24 0/48 0/48 0/24 0/16 0/8 78 M m bal eat 52w52 1665 0 .960mg 2.88mg 5.40mg 7.08mg 10.3mg ubl car ek 9.09mg Z P<.0005 + 4.11mg 26.7mg 0/23 0/41 0/44 1/22 3/13 4/8 79 M f bcn eat 65w78 1344a 0 6.50mg 8.13mg 10.8mg 16.3mg Littlefield;jept,3,17-34;1980/pers.comm. ubl tcc ekr 66.5mg Z P<.0005 + 40.3mg 123.mg 1/400 1/196 0/130 0/64 22/65 liv hpc ekr 120.mg * P<.0005 + 61.6mg 389.mg 1/401 4/196 5/130 1/64 4/65 80 M f bcn eat 15m24 1344b 0 4.88mg 6.09mg 8.13mg 12.2mg liv hpc ekr 30.6mg * P<.0005 + 19.7mg 55.2mg 9/383 15/114 14/86 6/35 6/28 ubl tcc ekr 95.5mg Z P<.0005 + 48.6mg 234.mg 1/384 0/114 0/86 1/35 11/28 81 M f bcn eat 52w52 1344m 0 7.80mg 9.75mg 13.0mg 19.5mg ubl tcc ekr 150.mg Z P<.0005 + 70.7mg 457.mg 0/140 0/268 0/137 0/138 9/141 liv hpc ekr 226.mg * P<.2 + 92.4mg n.s.s. 0/140 2/268 0/137 3/138 1/141 82 M f bcn eat 60w60 1344n 0 7.80mg 9.75mg 13.0mg 19.5mg ubl tcc ekr 68.8mg Z P<.0005 + 41.1mg 128.mg 0/113 0/221 0/110 0/117 21/114 liv hpc ekr 747.mg * P<.2 + 184.mg n.s.s. 0/113 0/224 0/110 1/117 1/114 83 M f bcn eat 65w65 1344o 0 7.80mg 9.75mg 13.0mg 19.5mg ubl tcc ekr 45.8mg Z P<.0005 + 29.4mg 77.0mg 0/88 0/181 1/94 0/89 28/90 liv hpc ekr 199.mg * P<.07 + 86.2mg n.s.s. 0/88 1/182 1/94 4/90 1/90 84 M f bcn eat 69w69 1344r 0 5.85mg 7.80mg 9.75mg 13.0mg 19.5mg ubl tcc ekr 62.1mg Z P<.0005 + 42.0mg 97.3mg 0/183 1/271 0/265 0/175 1/90 36/85 liv hpc ekr 218.mg * P<.05 + 97.9mg n.s.s. 1/183 2/272 4/265 5/174 1/90 3/86 85 M f bcn eat 73w73 1344s 0 4.55mg 5.85mg 7.80mg 9.75mg 13.0mg 19.5mg ubl tcc ekr 64.1mg Z P<.0005 + 44.1mg 98.2mg 0/127 1/389 1/264 0/206 0/134 4/67 36/65 liv hpc ekr 147.mg * P<.05 + 86.0mg n.s.s. 0/128 2/389 5/264 6/206 5/134 1/67 0/65 86 M f bcn eat 78w78 1344t 0 3.90mg 4.55mg 5.85mg 7.80mg 9.75mg 13.0mg 19.5mg ubl tcc ekr 101.mg Z P<.0005 + 76.4mg 139.mg 1/400 4/999 1/796 1/383 3/269 1/267 5/131 62/121 liv hpc ekr 154.mg * P<.0005 + 105.mg 310.mg 1/401 17/999 7/792 7/383 7/268 6/267 6/131 7/121 87 M f bcn eat 24m24 1344u 0 3.90mg 4.55mg 5.85mg 7.80mg 9.75mg 13.0mg 19.5mg liv hpc ekr 33.6mg Z P<.0005 + 28.9mg 40.1mg 9/383 55/900 55/639 57/445 71/415 62/311 47/160 56/130 ubl tcc ekr 96.0mg Z P<.0005 + 77.4mg 121.mg 1/384 0/900 2/638 1/445 3/415 3/311 25/160 100/130 88 M f bcn eat 33m33 1344v 0 3.90mg 4.55mg 5.85mg 7.80mg 9.75mg 13.0mg liv hpc ekr 19.6mg * P<.008 + 10.1mg 409.mg 8/23 44/92 20/45 5/12 7/11 8/12 8/10 ubl tcc ekr 82.1mg Z P<.0005 + 44.2mg 179.mg 0/24 1/92 0/45 0/12 1/11 4/12 8/10 89 M f bcn eat 39w78 1344w 0 3.90mg 4.88mg 6.50mg 9.75mg liv hpc ekr 110.mg * P<.002 + 49.1mg 585.mg 1/401 1/186 3/128 1/64 4/63 ubl tcc ekr 142.mg * P<.004 + 57.7mg 1.16gm 1/400 0/184 2/128 1/64 4/63 90 M f bcn eat 9m24 1344x 0 2.93mg 3.66mg 4.88mg 7.31mg liv hpc ekr 19.1mg * P<.0005 + 12.1mg 35.2mg 9/383 13/108 10/66 5/35 9/33 ubl tcc ekr 97.2mg Z P<.0005 + 40.8mg 388.mg 1/384 1/108 0/66 0/35 6/33 91 M f bcn eat 52w78 1344y 0 5.20mg 6.50mg 8.67mg 13.0mg ubl tcc ekr 82.8mg Z P<.0005 + 44.8mg 185.mg 1/400 0/190 0/132 1/65 14/63 liv hpc ekr 156.mg Z P<.009 + 67.6mg 4.45gm 1/401 1/190 6/132 0/65 2/63 92 M f bcn eat 12m24 1344z 0 3.90mg 4.88mg 6.50mg 9.75mg liv hpc ekr 24.3mg * P<.0005 + 15.6mg 43.4mg 9/383 11/118 14/74 5/33 9/29 ubl tcc ekr 101.mg Z P<.0005 + 46.6mg 306.mg 1/384 0/118 1/74 1/33 7/29 93 M f bcn eat 23m24 2066m 0 13.0mg 16.2mg 19.5mg Fullerton;faat,18,193-199;1992/Nonoyama 1988/ pers.comm. liv mix aers 11.6mg Z P<.0005 + 7.97mg 18.3mg 5/92 51/91 (39/93 26/82) ubl mix aers 12.8mg Z P<.0005 + 10.3mg 16.1mg 1/87 29/90 58/90 63/82 ubl car aers 21.9mg Z P<.0005 17.1mg 28.7mg 0/87 14/90 40/90 48/82 liv mal aers 30.0mg Z P<.0005 21.2mg 46.3mg 1/92 31/91 23/93 (13/82) liv hpb aers 3.20gm * P<.5 521.mg n.s.s. 0/96 0/96 1/96 0/96 94 M f bcn eat 23m24 2066n 0 13.0mg 16.2mg 19.5mg ubl mix aer 10.4mg Z P<.0005 + 8.47mg 12.8mg 1/92 29/91 74/95 76/91 ubl car aer 21.7mg Z P<.0005 17.0mg 28.6mg 1/92 16/91 46/95 49/91 liv mix aer 29.8mg * P<.0005 + 22.7mg 41.8mg 1/93 28/94 35/96 27/92 liv mal aer 58.3mg * P<.0005 41.2mg 88.9mg 0/93 16/94 19/96 14/92 95 M m bcn eat 22m24 2066m 0 2.40mg 4.80mg 7.20mg ubl mix aers 3.87mg Z P<.0005 + 3.09mg 4.93mg 0/88 4/86 50/86 82/90 ubl car aers 9.41mg Z P<.0005 7.03mg 13.0mg 0/88 1/86 13/86 59/90 liv mix aers 3.26gm * P<1. 27.1mg n.s.s. 19/92 18/90 15/88 19/87 liv mal aers no dre P=1. 64.3mg n.s.s. 9/92 5/90 7/88 5/87 liv hpb aers no dre P=1. 25.9mg n.s.s. 1/96 0/96 0/96 0/96 96 M m bcn eat 22m24 2066n 0 2.40mg 4.80mg 7.20mg ubl mix aer 9.05mg Z P<.0005 + 6.85mg 12.3mg 0/90 0/91 23/91 57/95 ubl car aer 26.4mg Z P<.0005 17.3mg 43.2mg 0/90 0/91 9/91 23/95 liv mix aer 69.0mg Z P<.2 22.2mg n.s.s. 5/93 4/94 10/94 (1/95) liv mal aer no dre P=1. 164.mg n.s.s. 3/93 1/94 2/94 0/95 97 M f cd1 eat 78w78 66a 0 32.5mg Epstein(review) {irdc};stev,6,103-154;1976 liv hpt e 21.3mg P<.0005 13.5mg 37.3mg 1/57 30/66 liv nod e 76.2mg P<.0005 37.1mg 218.mg 0/57 10/66 lun ade e 354.mg P<.6 56.0mg n.s.s. 6/57 9/66 98 M f cd1 eat 53w92 1635m 0 22.5mg Weikel;jcph,19,591-604;1979/pers.comm. liv hpc e 7.65mg P<.0005 + 5.10mg 11.9mg 0/60 46/58 99 M m cd1 eat 78w78 66a 0 30.0mg Epstein(review) {irdc};stev,6,103-154;1976 liv hpt e 22.5mg P<.0005 12.7mg 56.5mg 4/47 24/53 lun ade e no dre P=1. 155.mg n.s.s. 8/47 1/53 100 M m cd1 eat 53w92 1635m 0 20.7mg Weikel;jcph,19,591-604;1979/pers.comm. liv hpc e 13.5mg P<.0005 + 8.67mg 22.7mg 1/57 33/58 ubl pam e 34.5mg P<.0005 + 19.2mg 71.1mg 0/57 16/58 ubl tcc e 34.5mg P<.0005 19.2mg 71.1mg 0/57 16/58 kid mix e 86.5mg P<.003 37.3mg 375.mg 0/57 7/58 liv hpa e 639.mg P<.8 + 53.1mg n.s.s. 6/57 7/58 101 M m cen eat 52w52 1477 0 36.0mg Becker;canr,42,3918-3923;1982 liv mix kr 5.61mg P<.3 1.13mg n.s.s. 5/8 7/8 102 M f cf1 eat 52w52 469 0 39.0mg Newberne;txap,41,535-546;1977 mgl car e 14.6mg P<.0005 7.28mg 36.3mg 0/29 11/30 liv lcc e 16.5mg P<.0005 + 7.98mg 43.7mg 0/29 10/30 lun tum e no dre P=1. 60.3mg n.s.s. 0/29 0/30 103 M m cf1 eat 52w52 469 0 36.0mg liv lcc e 31.4mg P<.006 + 11.9mg 290.mg 0/31 5/28 lun ade e 149.mg P<.5 22.3mg n.s.s. 1/31 2/28 104 M f cva eat 30m30 2034u : 0 6.50mg 13.0mg 26.0mg Wolff;jtxe,33,327-348;1991/pers.comm. liv mix er 4.36mg Z P<.0005 + 2.73mg 7.59mg 4/24 14/24 22/24 23/24 liv hpc er 10.3mg * P<.0005 + 5.71mg 23.4mg 2/24 7/24 14/24 9/24 ubl mix er 54.8mg Z P<.0005 + 26.5mg 125.mg 0/24 0/24 0/24 12/24 ubl tcc er 63.5mg Z P<.0005 + 28.8mg 161.mg 0/24 0/24 0/24 10/24 105 M m cva eat 30m30 2034s : 0 6.00mg 12.0mg 24.0mg ubl mix er 3.59mg Z P<.0005 + 2.13mg 5.95mg 0/24 9/24 22/24 24/24 ubl tcc er 5.20mg Z P<.0005 + 2.95mg 8.96mg 0/24 5/24 17/24 21/24 liv mix er 7.43mg Z P<.0005 + 3.53mg 22.2mg 8/24 6/24 10/24 9/24 106 M f cvy eat 30m30 2034w : 0 6.50mg 13.0mg 26.0mg liv mix er 2.02mg Z P<.0005 + 1.12mg 4.04mg 16/24 23/24 23/24 24/24 liv hpc er 7.94mg Z P<.0005 + 4.06mg 14.7mg 0/24 6/24 10/24 11/24 ubl mix er 69.0mg Z P<.0005 + 31.1mg 188.mg 0/24 0/24 1/24 8/24 ubl tcc er 69.0mg Z P<.0005 + 31.1mg 188.mg 0/24 0/24 1/24 8/24 107 M m cvy eat 30m30 2034v : 0 6.00mg 12.0mg 24.0mg ubl mix er 1.56mg Z P<.0005 + .643mg 3.35mg 0/24 8/24 15/21 18/23 liv mix er 4.23mg * P<.0005 + 1.76mg 15.9mg 14/24 11/24 11/21 7/23 ubl tcc er 4.30mg Z P<.0005 + 1.81mg 8.38mg 0/24 3/24 12/21 15/23 108 M f ifc eat 64w64 1447 0 65.0mg Wood;ejca,6,433-440;1970 liv mix 4.78mg P<.0005 + 2.16mg 9.44mg 0/17 33/34 liv hpt 5.95mg P<.0005 3.13mg 11.1mg 0/17 32/34 ubl car 565.mg P<.4 + 92.0mg n.s.s. 0/17 1/34 ubl pam 565.mg P<.4 + 92.0mg n.s.s. 0/17 1/34 109 M m ifc eat 64w64 1447 0 60.0mg liv mix 36.1mg P<.005 + 15.5mg 260.mg 0/13 7/20 ubl car 36.1mg P<.005 + 15.5mg 260.mg 0/13 7/20 liv hpt 43.7mg P<.01 17.7mg 1.94gm 0/13 6/20 ubl pam 69.8mg P<.04 + 24.0mg n.s.s. 0/13 4/20 110 M f ifm eat 60w60 1069m 0 65.0mg Wood;ejca,5,41-47;1969 liv mix 19.6mg P<.0005 + 10.9mg 39.8mg 0/31 17/32 liv hpt 31.5mg P<.0005 16.1mg 74.4mg 0/31 12/32 ubl mix 44.9mg P<.0005 + 21.1mg 131.mg 0/31 9/32 111 M f ifm gav 60w60 1069n 0 22.9mg liv ade 91.2mg P<.2 14.8mg n.s.s. 0/31 1/18 112 M m ifm eat 60w60 1069m 0 60.0mg liv mix 42.9mg P<.002 + 19.3mg 183.mg 1/42 9/31 liv hpt 77.8mg P<.004 29.5mg 475.mg 0/42 5/31 113 M m ifm gav 60w60 1069n 0 19.0mg ubl mix 12.9mg P<.0005 + 5.23mg 46.5mg 0/42 6/21 liv mix 57.2mg P<.3 11.2mg n.s.s. 1/42 2/21 114 M f r3m eat 60w60 1069m 0 65.0mg ubl mix 104.mg P<.07 + 35.7mg n.s.s. 0/15 4/30 liv mix no dre P=1. 134.mg n.s.s. 0/15 0/30 115 M m r3m eat 60w60 1069m 0 60.0mg ubl mix 51.0mg P<.04 + 23.0mg n.s.s. 0/10 8/34 ubl car 86.0mg P<.1 32.6mg n.s.s. 0/10 5/34 liv mix no dre P=1. + 54.4mg n.s.s. 1/10 3/34 116 P b rhe eat 5y26 2004 : 0 6.77mg Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm. npl adc jw 33.0mg P<.1 5.37mg n.s.s. 0/16 1/5 tba mal Wjw no dre P=1. 9.02mg n.s.s. 6/74 1/10 117 R f cdr eat 15m24 1112 0 3.00mg 12.5mg Weisburger;jnci,67,75-88;1981 mgl mix ae 4.75mg * P<.0005 + 2.48mg 10.4mg 0/32 8/16 7/10 liv hpc ae 26.9mg * P<.02 + 9.24mg n.s.s. 0/32 2/16 2/10 118 R m cdr eat 15m24 1112 0 2.40mg 10.0mg liv hpc ae 3.78mg * P<.0005 + 1.78mg 9.52mg 1/32 3/16 10/10 119 R m f3d eat 24m24 1756 0 .320mg 1.60mg 8.00mg Ogiso;txpy,13,257-265;1985 liv hpc e .640mg * P<.0005 + .385mg 1.11mg 0/30 3/29 26/28 23/23 liv thc e .697mg * P<.0005 .421mg 1.21mg 0/30 3/29 25/28 23/23 liv ghc e no dre P=1. 28.2mg n.s.s. 0/30 0/29 1/28 0/23 liv clc e no dre P=1. 1.52mg n.s.s. 0/30 0/29 0/28 0/23 120 R f hza eat 36w54 1063m 0 10.0mg Morris;canr,29,2145-2156;1969 mam tum es .841mg P<.0005 + .286mg 2.98mg 0/5 8/9 eac car es 13.8mg P<.4 2.24mg n.s.s. 0/5 1/8 liv tum es no dre P=1. 5.00mg n.s.s. 0/5 0/9 121 R f hza eat 44w60 1063n 0 11.0mg mam tum es .981mg P<.0005 + .367mg 2.96mg 3/16 15/16 eac car es 8.75mg P<.02 3.00mg n.s.s. 0/16 4/16 liv tum es no dre P=1. 12.1mg n.s.s. 0/16 0/16 122 R f lev eat 56w56 1635m 0 15.0mg Weikel;jcph,19,591-604;1979/pers.comm. liv mix 1.53mg P<.0005 + 1.05mg 2.28mg 0/60 60/70 ski mix 12.3mg P<.0005 + 6.60mg 33.3mg 1/60 16/70 mgl mix no dre P=1. + 16.4mg n.s.s. 16/60 14/70 123 R m lev eat 56w56 1635m 0 12.0mg liv mix s 1.17mg P<.0005 + .796mg 1.76mg 1/60 61/70 ski mix s 20.1mg P<.09 + 7.46mg n.s.s. 5/60 13/70 mgl tum s 54.4mg P<.06 + 16.5mg n.s.s. 0/60 3/70

Mutagenicity in Salmonella: positive
SMILES Code for 2-Acetylaminofluorene: C12C3=C(C=CC=C3)CC1=CC(=CC=2)NC(C)=O
InChI Code for 2-Acetylaminofluorene: InChI=1/C15H13NO/c1-10(17)16-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)15/h2-7,9H,8H2,1H3,(H,16,17)
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for 2-Acetylaminofluorene: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10